
The impact of Reconcile® on the success of behavior modification training
Results from clinical trials of more than 400 dogs demonstrate the positive impact of Reconcile® on behavior modification training.[1]
Reconcile® is a once-daily, chewable flavored tablet. It is available in four dosing sizes based on your dog's
weight. Reconcile® is available in 8, 16, 32, 64 mg chewable tablet
strengths that can be given with or without food. Your veterinarian will prescribe
the right amount for your dog, and is always your best source of information
for any questions related to giving your pet Reconcile®.
What role does behavior modification play?
Starting your dog on Reconcile® at the same time as beginning a simple
training program gives you the best chance of treating separation anxiety.
Your veterinarian will provide you a step-by-step guide to help you understand
and implement the training program used with Reconcile®, also called
the BOND™ simple training plan. Combining these simple training techniques
with Reconcile® chewable tablets has been proven to work faster and better
than training alone.
The BOND™ simple training plan includes four steps and focuses on reinforcing
positive behavior:
- Be positive
- Only reward calm behavior
- No more drama when you come and go
- Develop your dog's independence
More information on the BOND™ training plan can be found at BOND™ Simple
Training Plan.
Important Safety Information
- The most common adverse reactions recorded during clinical trials with Reconcile® were calm or lethargy, reduced appetite, vomiting, shaking, diarrhea, restlessness, excessive vocalization, aggression, and, in infrequent cases, seizures.
- Reconcile® chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.
- A six week washout interval should be observed following discontinuation of therapy with Reconcile® chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.
- For full product label, including complete safety information, click here.